全国性研究:糖尿病合并下肢动脉粥样硬化病变患者行药物洗脱或非药物洗脱腔内治疗的结果
该全国性回顾性观察注册研究纳入2013至2015年瑞典血管注册中因间歇性跛行(n=1948)或慢性肢体威胁性缺血(n=3353)行血管或腔内手术的患者,评估药物洗脱技术在有或无糖尿病患者中的效果。中位随访607天,主要复合终点为大截肢和/或死亡;中位522天随访再干预。IC患者及再干预需求方面无差异。
要点
- 糖尿病CLTI患者药物洗脱治疗较非药物洗脱调整后截肢或死亡风险更低(HR 0.712)。
- 间歇性跛行患者中药物洗脱与非药物洗脱无差异。
- 再干预需求在有或无糖尿病患者中均无差异。
核心结论
- 该全国性随访研究提示药物洗脱治疗对糖尿病CLTI患者可能有获益,结果需在前瞻性随机研究中评估和确认。
研究设计与样本
- 回顾性观察注册研究,纳入2013至2015年瑞典血管注册(Swedvasc)中因间歇性跛行(n=1948)或慢性肢体威胁性缺血(n=3353)行血管或腔内手术的所有瑞典患者。
- 糖尿病患者在瑞典国家糖尿病注册(NDR)登记,与非糖尿病患者分别评估。
主要发现
- 间歇性跛行患者中药物洗脱与非药物洗脱无差异。
- 再干预需求在有或无糖尿病患者中,药物洗脱与非药物洗脱均无差异。
临床怎么用
- 作者认为该研究提示药物洗脱治疗对糖尿病CLTI患者可能有获益,但结果需在前瞻性随机研究中评估和确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Paclitaxel eluting balloons and stents reduce the development of intimal hyperplasia and restenosis rate after endovascular treatment for peripheral arterial disease (PAD) in the lower extremities. As diabetes mellitus (DM) worsens the prognosis in PAD patients after invasive endovascular treatment, we assessed the effects of drug eluting technology for PAD with special focus on effects in patients with and without DM. All Swedish patients registered in the Swedish vascular registry Swedvasc after vascular or endovascular surgery for intermittent claudication, IC; (n=1948) or chronic limb threatening ischemia, CLTI (n=3353) in 2013 to 2015 were followed up regarding a composite of either major amputation and/or mortality during median 607 days and for reinterventions for PAD during median 522 days. Patients with DM registered in the Swedish National Diabetes Registry (NDR) and patients without DM were evaluated separately. The 201 CLTI patients with DM treated with drug eluting methods had a lower adjusted risk for amputation or mortality after adjustment than the 1476 CLTI patients with DM treated without drug eluting methods (hazard ratio [HR] 0.712 [0.562-0.901], P=.005). There were no differences among IC patients. Regarding the need for reinterventions for PAD, there were no differences between patients treated with and without drug eluting methods, irrespectively of the presence or absence of DM. In conclusion, this nationwide follow-up study indicated potential benefits of drug eluting treatment in CLTI patients with diabetes. The results need to be evaluated and confirmed in prospective randomized studies.Clinical ImpactThis retrospective observational registry trial combines national registries for vascular surgical procedures and diabetes mellitus to clarify results of drug eluting technology in treating diabetic subjects with intermittent claudication or chronic limb threatening ischemia compared to treatment of non-diabetic subjects. As earlier proposed and showed in this trial, there may be an implication for a beneficial treatment efficacy with drug eluting therapy in the diabetic population with PAD compared to the non-diabetic population. A finding worth further exploration.
引用
- Fransson T, Sturedahl AD, Resch T, et al. Nationwide Study of the Outcome of Treatment of Lower Extremity Atherosclerotic Lesions With Endovascular Surgery With or Without Drug Eluting Methods in Patients With Diabetes. J Endovasc Ther. 2024. PMID: 38577781. doi:10.1177/15266028241241967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。